Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.

Q2 Pharmacology, Toxicology and Pharmaceutics Drugs in Context Pub Date : 2023-01-01 DOI:10.7573/dic.2023-1-8

Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris

{"title":"Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience.","authors":"Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris","doi":"10.7573/dic.2023-1-8","DOIUrl":null,"url":null,"abstract":"Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52-week treatment period.Methods: We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity.Results: Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16.Conclusion: Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"12 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/03/dic-2023-1-8.PMC10108662.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2023-1-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52-week treatment period.

Methods: We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity.

Results: Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16.

Conclusion: Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利桑单抗治疗掌足底银屑病的有效性:52周的意大利现实生活经验。

背景:关于掌跖牛皮癣(PP)治疗的数据很少，这是一个治疗挑战。本研究旨在评估risankizumab在52周治疗期内累及掌足底的银屑病患者群体中的疗效和安全性。方法:我们对一组有或无其他皮肤部位受累的PP患者进行了回顾性分析。在基线和4、16、28和52周后评估掌跖牛皮癣面积和严重程度指数(ppPASI)，以评估PP的严重程度。结果:16例患者入组。ppPASI90应答率在观察期间不断升高，在第4、16、28和52周分别为18.7%、62.2%、75.0%和81.2%。只有两名患者在第16周因无效而暂停治疗。结论:我们来自16例患者的一系列数据显示，利桑单抗可能是PP患者有效且安全的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.